# PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

> **NCT06792162** · PHASE2 · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Carilizumab and Apatinib

## Key facts

- **NCT ID:** NCT06792162
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-20
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06792162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06792162, "PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06792162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*